Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MG4101
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
AlloNK® + Rituximab Safety & Efficacy In Relapsing B-Cell Dependent Rheumatologic Diseases
Details : MG4101 is a drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Arthritis, Rheumatoid.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 25, 2025
Lead Product(s) : MG4101
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GCC2005 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, T-Cell.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
November 21, 2024
Lead Product(s) : AB-101
Therapeutic Area : Immunology
Study Phase : Phase I
Recipient : IRIS Research and Development, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AB-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Arthritis, Rheumatoid.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 03, 2024
Lead Product(s) : AB-101
Therapeutic Area : Immunology
Highest Development Status : Phase I
Recipient : IRIS Research and Development, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AB-101,Acimtamig,Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Jefferies
Deal Size : $167.0 million
Deal Type : Public Offering
Artiva upsizes IPO to $167 million as NK cell therapy biotech heads to Nasdaq
Details : The net proceeds will be used to fund the clinical development of the company's lead product AlloNK (AB-101), which is being evaluated for the treatment of r/r Hodgkin Lymphoma.
Product Name : AlloNK
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 18, 2024
Lead Product(s) : AB-101,Acimtamig,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Jefferies
Deal Size : $167.0 million
Deal Type : Public Offering
Lead Product(s) : AB-101,Cyclophosphamide,Rituximab
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Artiva Biotherapeutics Receives FDA Fast Track Designation for AlloNK® in Lupus Nephritis
Details : AlloNK (AB-101) is an allogeneic NK cell therapy designed to enhance antibody-dependent cellular cytotoxicity in combination with rituximab or obinutuzumab for treating lupus nephritis.
Product Name : AlloNK
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 22, 2024
Lead Product(s) : AB-101,Cyclophosphamide,Rituximab
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AB-101
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AB-101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lupus Nephritis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 20, 2024
Lead Product(s) : AB-101
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AB-101,Rituximab
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AlloNK (AB-101) is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with Combination with Rituximab in Lupus Nephritis.
Product Name : AlloNK
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 16, 2023
Lead Product(s) : AB-101,Rituximab
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 2 Study of AFM13 in Combination with AB-101 in Subjects with R/R HL and CD30+ PTCL
Details : AFM13 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hodgkin Disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 01, 2023
Lead Product(s) : Acimtamig,AB-101
Therapeutic Area : Oncology
Study Phase : IND Enabling
Recipient : Affimed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AFM13 is a first-in-class innate cell engager (ICE®) that uniquely leverags the power of the innate immune system by engaging and activating natural killer (NK) cells and macrophages to destroy CD30-positive hematologic tumors.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 23, 2023
Lead Product(s) : Acimtamig,AB-101
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Recipient : Affimed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AB-201
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AB-201 is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 10, 2023
Lead Product(s) : AB-201
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable